港股创新药板块尾盘持续拉升，荣昌生物涨超13%，泰格医药、凯莱英涨超9%，药明生物、信达生物 涨超5%。 ...

Group 1 - The A-share market experienced narrow fluctuations on January 7, with coal, chips, and innovative drug sectors leading in gains. The Southern Innovative Drug ETF (159858.SZ) rose by 1.60%, and Baijie Shenzhou increased by 3.29% [1] - The Chinese innovative drug industry is expected to undergo a value return and structural reshaping by 2025, with a shift in core logic towards product strength, platform capability, and global operational ability [1] - Policies are transitioning from encouraging innovation to a new phase of systematic and precise guidance, providing institutional support for original innovation [1] Group 2 - Capital is concentrating on companies with core technology platforms, clear clinical value, and global potential, favoring mid-to-late-stage projects in areas such as ADC, bispecific antibodies, CGT, and AI drug development [1] - The transaction amount for innovative drugs going overseas has reached a historical high, with deepening collaboration models [1] - Domestic ADC and bispecific antibody products have been approved and show globally leading data, while breakthroughs have been made in small molecule drugs targeting "undruggable" targets, and significant progress has been observed in cell therapies and nucleic acid drugs [1] Group 3 - The industry is transitioning from following innovation to original innovation, and from technology input to systematic output [1] - The trend for the innovative drug industry is positive, with strengthened global competitiveness, ongoing international expansion, and gradual realization of commercial profitability [1] - The medical device industry is experiencing a calming of influencing factors, with accelerated innovation and internationalization [1] Group 4 - The innovative drug industry is showing enhanced innovation vitality and significant internationalization results, with sufficient long-term development momentum [1] - The Southern Innovative Drug ETF (159858.SZ) can focus on innovative drugs and the industry chain, sharing the growth dividends of truly competitive companies amid industry differentiation and seizing opportunities for value reshaping [1]

1月7日，科创创新药ETF国泰（589720）涨超3.6%，创新与出海主线获市场关注。 科创创新药ETF国泰（589720）聚焦科创板创新药企业，跟踪汇聚30家代表性优质公司的上证科创板创 新药指数，以高成长biotech为主，产品20%涨跌幅限制使其更贴合板块波动。从业绩表现来看，2024年 9月24日至2025年10月31日市场反弹期间，科创新药/恒生港股通创新药指数涨幅分别为 143.70%/135.34%，科创新药指数或有助于在市场风险偏好回升时更好地分享科创板的弹性。 （文章来源：每日经济新闻） 中泰证券指出，2025年医药板块迎来强势反弹，行情由AI+和创新药推动，反映出中国创新能力的质的 飞跃及出海逻辑兑现。化学制药等细分行业经历政策改革后呈现复苏。创新药出海从"叙事"进入兑现阶 段，交易金额创新高，国内政策全链条支持创新药，首次增设商保目录打开支付空间。CRO/CDMO行 业内外需共振，全球投融资恢复带动订单增长，供给端逐步出清，板块有望迎来"戴维斯双击"。2026年 医药板块投资思路将延续创新成长+困境反转逻辑，建议关注创新药及产业链、需求复苏及经营拐点等 方向。 ...

Core Viewpoint - The Hong Kong innovative drug sector continues its strong performance, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index rising over 2%, indicating a bullish trend in the market [1] Industry Dynamics - Research Development: Innovent Biologics has received approval for its CTLA-4 monoclonal antibody "Daboshu" as the first domestically approved CTLA-4 inhibitor, filling a gap in the domestic dual immune new adjuvant therapy field [1] - Business Development: Ginkgo Bioworks has established a collaboration with AstraZeneca worth over $2 billion, setting a record for domestic clinical-stage small molecule anti-cancer drug collaborations [1] Market Activity - The Hong Kong Stock Connect Innovative Drug ETF managed by E Fund (159316) saw a significant increase in trading volume, exceeding 600 million yuan, indicating heightened investor interest [1] - The market's expectations for a potential interest rate cut by the Federal Reserve have increased, with the probability of a rate cut in March 2026 rising to over 40%, which may positively impact the Hong Kong innovative drug sector [1]

Core Viewpoint - The Hong Kong stock market is experiencing significant growth in the biopharmaceutical sector, with the innovative drug ETF showing strong performance and trading activity [1][2]. Group 1: Market Performance - The Hong Kong innovative drug ETF (159567) increased by 3.27%, with a trading volume exceeding 1.207 billion yuan and a turnover rate over 14% [1]. - Notable individual stocks include Tongyu Kang Pharmaceutical-B rising over 11%, Ascentage Pharma-B up over 7%, and Kangfang Biotech increasing over 6% [2]. Group 2: Industry Growth - By 2025, China's innovative drug business development (BD) is expected to see explosive growth, with total foreign licensing transaction amounts reaching $135.655 billion (approximately 948.3 billion yuan) and a record 157 transactions [2]. - China has surpassed the United States to become the world's largest source of drug licensing, with 90% of the top 20 global multinational pharmaceutical companies collaborating with Chinese innovative drug pipelines [2]. Group 3: Policy Support - The implementation of a dual directory for medical insurance and commercial insurance will begin on January 1, 2026, adding 114 new drugs to the basic medical insurance directory, including 50 first-class innovative drugs [2]. Group 4: Technological Advancements - The integration of AI is accelerating the drug development process, with companies like Insilico Medicine significantly shortening the candidate compound identification cycle [2]. - The commercialization of cutting-edge fields such as ADC, bispecific antibodies, and small nucleic acids is accelerating, with 76 innovative drugs expected to be approved in China by 2025, surpassing the 48 expected in 2024 [2]. Group 5: ETF Composition - The Hong Kong innovative drug ETF closely tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index, featuring leading stocks such as BeiGene, Innovent Biologics, and 3SBio, with a high proportion of innovative pharmaceutical companies [2].

Core Viewpoint - The 2026 investment outlook for the A-share market highlights the impact of geopolitical changes and technological innovations, particularly in AI, on capital markets, while addressing potential challenges and opportunities for investors [3][4][31]. Market Overview - The A-share market has shown a bullish trend, with major indices recording their second consecutive year of positive annual K-lines, particularly the Shanghai Composite Index reaching a 10-year high [4][32]. - Historical data indicates that the A-share market has never recorded three consecutive years of positive annual K-lines, raising questions about the potential for a new cycle in 2026 [4][33]. Key Drivers of the Bull Market - The bull market is driven by several core factors, including the government's strong emphasis on the stock market, a prolonged low-interest-rate environment favoring dividend stocks, and the stock market's emergence as a leading asset class with mid-term growth potential [5][34][36]. - The market's dynamics are influenced by both short-term and mid-term variables, with the potential emergence of new long-term cycle variables that may not be immediately recognized by investors [4][33]. Market Consensus and Analysis - The consensus among analysts is that the government is committed to high-quality capital market development, as evidenced by various supportive policies introduced since early 2024 [5][34]. - The low-interest-rate environment has been beneficial for dividend-paying stocks, which have become a core component of long-term investment strategies [5][34]. - The stock market is increasingly viewed as a primary asset class with significant mid-term growth potential, especially as real estate's role in economic growth diminishes [5][34]. Geopolitical and Economic Context - The ongoing geopolitical tensions, particularly between the US and China, are reshaping the investment landscape, with implications for market dynamics and corporate performance [8][39]. - The competition between the US and China is recognized as a critical geopolitical issue, influencing market sentiment and investment strategies [8][39]. Market Valuation and Structural Changes - The valuation framework of the A-share market is undergoing significant changes, with a notable divergence in performance between consumer stocks and technology sector stocks [40]. - The market's valuation adjustments may reflect a broader shift towards innovation-driven growth, necessitating a reevaluation of traditional investment strategies [40][43]. Investment Themes for 2026 - Key investment themes for 2026 include the continued focus on AI and technology innovation, resource commodities like gold, silver, and copper, and the potential for price increases in various sectors due to supply-demand dynamics [22][26][28]. - The performance of innovative pharmaceuticals is also highlighted, with expectations for continued growth driven by successful business development transactions and advancements in drug development [26][27].

Core Insights - The innovative drug ETF Tianhong (517380) has seen significant trading activity, with a transaction volume of 28.36 million yuan, and the underlying index, the Hang Seng Shanghai Shenzhen Hong Kong Innovative Drug Select 50 Index (HSSSHID), has risen nearly 3%, marking a strong performance with several constituent stocks like Kelaiying (06821) and Yifang Bio (688382) showing notable gains [1] Product Highlights - The innovative drug ETF Tianhong (517380) spans the markets of Shanghai, Hong Kong, and Shenzhen, selecting 50 leading innovative drug companies, with 40% from Hong Kong and 60% from A-shares, covering key areas such as biopharmaceuticals and chemical pharmaceuticals [1] Relevant Events - The new national medical insurance directory and the first commercial insurance innovative drug directory were implemented on January 1, 2026, adding 50 types of first-class innovative drugs and 19 types of commercial insurance drugs, establishing a "medical insurance + commercial insurance" payment loop. In 2025, China approved 76 innovative drugs, a significant increase of 58.3% from 48 in 2024, with over 80% being domestically produced, laying a foundation for sales growth in 2026 [1] Industry Trends - China's innovative drug licensing abroad has seen a breakthrough, with total transaction amounts reaching 135.655 billion USD by December 31, 2025, including upfront payments of 7 billion USD and 157 transactions, significantly surpassing the 51.9 billion USD and 94 transactions recorded in 2024 [2] - According to Zhongtai Securities, the pharmaceutical market is expected to continue benefiting from innovation-driven growth and industrial upgrades, with investment strategies for 2026 focusing on innovative drugs and their supply chains, demand recovery, and AI-related opportunities [2] Market Dynamics - The current innovative drug market differs from the 2019-2021 period, as the focus has shifted from narrative to actual execution, with transaction amounts reaching new highs, reflecting a transition in China's innovative capabilities from quantity to quality. Continuous policy support for innovative drugs, including the introduction of a commercial insurance directory, is expected to enhance payment options [3] - Companies with mature products successfully entering multinational corporations (MNCs) and those with strong platform advantages in cutting-edge technologies (such as ADC, small nucleic acids, and bispecific antibodies) are recommended for attention, along with potential collaboration opportunities [3]

Group 1 - The core viewpoint of the news is that the Hong Kong stock market's innovative drug index is experiencing growth, indicating a positive trend in the pharmaceutical sector, particularly in innovative drugs [1] - As of 09:40, the Hong Kong Stock Connect innovative drug index rose by 1.59%, with individual stocks like Kangfang Biotech increasing over 3%, and others such as Kelun-Bio, CSPC Pharmaceutical, and Hansoh Pharmaceutical rising over 2% [1] - The report from Donghai Securities suggests that by 2026, China's pharmaceutical and biotechnology industry will enter a new era of innovative drugs, which will gradually dominate the sector, supported by the complementary relationship between medical insurance and commercial insurance [1] Group 2 - The Hong Kong Stock Connect innovative drug ETF, managed by Harvest (520970), tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks accounting for over 71.71% of the total weight [2] - The management and custody fees for the Harvest innovative drug ETF are 0.60% per year, making it suitable for both ordinary investors as a long-term investment tool and for professional investors seeking flexible trading options [2]

Core Viewpoint - The Hong Kong stock market's innovative drug sector has shown significant growth, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3.6% and 36 out of 37 covered companies reporting gains, indicating a strong performance in the sector [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a rapid increase of over 3.6% [1] - 36 out of the 37 innovative drug companies covered by the ETF reported positive performance, with Syncona Health-B leading with a surge of over 13% [1] - Major player Kangfang Biologics saw an increase of nearly 5% [1] Group 2: Regulatory Approvals and Developments - Innovent Biologics' CTLA-4 monoclonal antibody "Daboshu" became the first domestically approved CTLA-4 inhibitor, filling a gap in the dual immune new adjuvant therapy field in China [1] - AstraZeneca and Daiichi Sankyo's TROP2 ADC "Dercutuzumab" received approval for breast cancer indications, further solidifying the advantages in the ADC sector [1] Group 3: Industry Trends and Projections - The innovative drug business development (BD) transactions are on the rise, with the total authorization amount for Chinese innovative drugs reaching $135.655 billion and 157 transactions recorded in 2025, both setting historical highs [1] - China's pipeline of new drugs now accounts for 30% of the global total, ranking second worldwide [1] - Analysts suggest that the pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global expansion, with a potential performance inflection point and valuation restructuring expected by 2026 [1][2] Group 4: Investment Strategies - Huafu Securities maintains that the long-term logic of pharmaceutical innovation remains unchanged, with the recent positive market performance indicating good opportunities for innovative drugs and devices in 2026 [2] - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: pure focus on innovative drugs, significant weight on leading companies, and better risk control [2] - For investors looking to reduce volatility while still focusing on innovative drugs, the only drug ETF (562050) and its associated fund (024986) are recommended, which focus on the top 50 A-share pharmaceutical companies and include a significant portion of traditional Chinese medicine [2][3]

Group 1 - The A-share market saw a collective rise in innovative drug concept stocks on January 7, with notable gains including a 20% increase for Beibete-U and over 17% for Yinos. [1] - Other significant performers included Chengdu XianDao with a 13% rise, and Panlong Pharmaceutical reaching a 10% increase. [1] - Additional stocks such as Yangguang Nuohuo and Zhaoyan New Drug also experienced gains exceeding 9% and 7% respectively. [1] Group 2 - The table lists various stocks with their respective codes, showing percentage increases, total market capitalization, and year-to-date performance. [2] - Beibete-U (688759) had a market cap of 18.6 billion with a year-to-date increase of 42.46%. [2] - Yinos (688710) reported a market cap of 7.611 billion and a year-to-date increase of 22.29%. [2] - Chengdu XianDao (688222) had a market cap of 12.2 billion and a year-to-date increase of 29.59%. [2] - Other stocks listed include Panlong Pharmaceutical (002864) with a market cap of 3.706 billion and a year-to-date increase of 13.07%, and Yangguang Nuohuo (688621) with a market cap of 8.188 billion and a year-to-date increase of 17.63%. [2]